CMS Withdrawal Shakes Skin Substitute Market, Sending ORGO and MDXG Stocks Tumbling

Shares in Organogenesis (ORGO) and MiMedx (MDXG) fell after the Centers for Medicare & Medicaid Services (CMS) withdrew key coverage decisions for skin substitute products. The move affects treatments for diabetic foot ulcers and venous leg ulcers, creating uncertainty for several medical firms. Analysts now predict a shift in marketplace competition as a result.

The CMS decision involves the withdrawal of Local Coverage Determinations (LCDs) for certain skin substitute grafts and cellular products. These LCDs previously governed reimbursement for treatments like Apligraf, Regranex, Grafix, PriMatrix, and AmnioExcel. Companies impacted include Organogenesis, MiMedx, Integra LifeSciences, and Vericel.

CMS had delayed implementing the LCDs until January 1 due to an ongoing review. Their withdrawal now opens the marketplace to around 312 additional products, according to BTIG analyst Ryan Zimmerman. He suggested that low-cost providers like ORGO could still thrive despite his reduced confidence in the company’s 2026 outlook. Meanwhile, Craig-Hallum analyst Chase Knickerbocker argued that the withdrawal would intensify competition for MiMedx. The change removes previous restrictions, allowing more products to enter the stock market.

The CMS withdrawal removes coverage barriers for dozens of skin substitute products. This move is likely to reshape competition among medical firms specialising in wound care. Share prices for ORGO and MDXG dropped following the announcement, reflecting investor concerns over future stock market dynamics.